Cholesterol is a lipid molecule essential for human physiology and is required for cell membranes, steroid hormone synthesis, bile acid production and other biological processes. It is transported through the bloodstream within lipoprotein particles because cholesterol itself is poorly soluble in water. The body obtains cholesterol from food and, importantly, synthesises substantial amounts internally, particularly in the liver. Blood cholesterol measurements therefore reflect the interaction between endogenous synthesis, intestinal absorption, lipoprotein transport, tissue uptake and excretion. Cholesterol is not intrinsically a harmful substance; the clinical issue is the concentration, distribution and duration of exposure to particular lipoprotein particles and the resulting risk of atherosclerotic cardiovascular disease.
Low-density lipoprotein is a major cholesterol-transporting particle and plays a causal role in atherosclerosis. LDL particles can enter the arterial wall, become modified and contribute to inflammatory plaque development. Higher cumulative exposure to LDL cholesterol is associated with greater atherosclerotic cardiovascular risk, while lowering LDL reduces that risk in appropriately selected populations. High-density lipoprotein participates in reverse cholesterol transport and other biological processes, but simply increasing HDL cholesterol has not consistently been shown to reduce cardiovascular events. This is why modern cardiovascular prevention focuses strongly on atherogenic lipoprotein exposure rather than treating HDL concentration as a standalone therapeutic target.
Cholesterol is transported in several classes of lipoprotein. Very-low-density lipoprotein transports triglyceride and cholesterol from the liver, while intermediate-density particles arise during VLDL metabolism and LDL is produced through subsequent processing. HDL participates in lipid transport between tissues and the liver. Non-HDL cholesterol represents cholesterol carried by potentially atherogenic lipoproteins and can be useful when triglycerides are elevated. Apolipoprotein B reflects the number of atherogenic lipoprotein particles and can provide additional risk information in selected circumstances. These measurements are related but not interchangeable, so interpretation depends on the clinical question and overall risk profile.
Blood cholesterol is influenced by genetics, diet, body composition, physical activity, metabolic conditions, medications, age and other factors. Familial hypercholesterolaemia is an inherited disorder in which impaired LDL clearance can produce markedly elevated LDL cholesterol from an early age and substantially increase premature cardiovascular risk. Secondary causes of elevated cholesterol can include hypothyroidism, some kidney disorders, liver conditions and particular medications. Dietary saturated fat can increase LDL cholesterol in many people, whereas replacing saturated fats with unsaturated fats can improve lipid profiles. The magnitude of dietary effects varies, and genetics can dominate in some disorders.
Lipid testing commonly includes total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. LDL may be calculated from other lipid measurements under appropriate circumstances or measured directly when calculation is unreliable. Non-fasting lipid testing is acceptable for many routine assessments, although fasting measurements can be useful in particular situations, especially when triglycerides are markedly elevated. A single measurement provides only a snapshot because lipid concentrations can vary over time. Cardiovascular risk assessment therefore combines lipid results with age, blood pressure, smoking, diabetes, kidney disease, family history and other factors rather than treating a cholesterol number as an isolated diagnosis.
Treatment of elevated atherogenic cholesterol can involve dietary modification, physical activity, weight management where appropriate and medicines. Statins reduce hepatic cholesterol synthesis and increase hepatic LDL-receptor activity, thereby lowering circulating LDL cholesterol and reducing cardiovascular events. Other medicines, including ezetimibe, PCSK9-directed therapies and selected newer agents, can provide additional LDL reduction for people with particular levels of risk or inadequate response to initial treatment. The appropriate target or intensity of treatment depends on overall cardiovascular risk and whether established cardiovascular disease or inherited lipid disorders are present.
Cholesterol is essential to normal physiology, so the objective of treatment is not to eliminate it from the body. Very low circulating LDL concentrations achieved through effective therapy can be physiologically tolerated, and clinical trials support substantial cardiovascular benefit from LDL reduction in appropriate populations. Nevertheless, medicines can produce adverse effects and treatment decisions must consider individual circumstances, interactions and adherence. Lifestyle interventions remain valuable but cannot reliably substitute for medication in every high-risk condition, particularly severe inherited hypercholesterolaemia or established cardiovascular disease.
Common misconceptions include equating cholesterol with dietary fat, assuming that high total cholesterol automatically means high cardiovascular risk, or believing that HDL can completely offset high LDL. Dietary cholesterol and circulating LDL are related but not identical concepts, and different dietary fats can have different effects on blood lipids. Cholesterol also has no direct relationship with whether a food tastes fatty. The clinically important issue is cumulative exposure to atherogenic lipoproteins and the person's overall vascular risk. Understanding Cholesterol therefore requires distinguishing the molecule itself from the lipoproteins that transport it and from the broader process of atherosclerotic cardiovascular disease.
